A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer
Status:
Recruiting
Trial end date:
2029-05-31
Target enrollment:
Participant gender:
Summary
HR-positive breast cancers accounts for about 50% to 60% of all breast cancer patients.
Neoadjuvant Chemotherapy is the core treatment mode for this type of breast cancer, and
endocrine therapy can be used in some low-risk patients. However, the pathological complete
response (pCR) rate obtained is low. HER2 is an important prognostic indicator and
therapeutic target for breast cancer. Nearly 60% of HR-positive breast cancers have low
expression of HER2, and antibody-drug conjugates (ADC) targeting HER2 may achieve better
efficacy in this subtype.